Tag: axonics

sacral neurmodulation system

Axonics announces US Food & Drug Administration approval for its sacral...

  Axonics, a medical technology company that has developed and is commercialising novel implantable rechargeable sacral neuromodulation (SNM) devices for the treatment of bladder and...
first US patient implanted with SNM Axonics

Axonics announces first commercial US patient implanted with its sacral neuromodulation...

  Axonics has announced the first US-based implantation of the Axonics r-SNM system subsequent to its clearance by the US Food & Drug Administration (FDA)...
ARTISAN Axonics

Axonics provides full one-year results from ARTISAN-SNM pivotal study

  Axonics announced the presentation of detailed one-year results from its ARTISAN rechargeable sacral neuromodulation (r-SMN) pivotal study at a plenary session at the joint...
SNM system FDA Axonics

Axonics announces agreement to supply sacral neuromodulation systems to leading urology...

  Axonics has announced that it has entered into an exclusive agreement to supply the Axonics rechargeable sacral neuromodulation (r-SNM) system to Adult Pediatric Urology...
SNM system FDA Axonics

Axonics announces US FDA approval for its sacral neuromodulation system

Axonics, a medical technology company that has developed and is commercialising a novel implantable rechargeable sacral neuromodulation (SNM) device for the treatment of urinary and...
first US patient implanted with SNM Axonics

Axonics announces FDA approval for the use of full-body MRI for...

Axonics have announced that the Food & Drug Administration (FDA) approved the use of full-body magnetic resonance imaging (MRI) using 1.5 Tesla MRI scanners...

Welkin Health announces partnership to implement a programme to support commercialisation...

Welkin Health, a privately-held patient relationship management software company has announced that it is partnering with Axonics, a company focused on the design, development,...
first US patient implanted with SNM Axonics

Axonics granted full-body MR-conditional CE mark for its sacral neuromodulation system

Axonics has announced that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging conditional labelling for the Axonics r-SNM...
first US patient implanted with SNM Axonics

Axonics announce positive clinical data from its ARTISAN sacral neuromodulation pivotal...

Axonics has disclosed positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the US Food and Drug Administration (FDA)...
first US patient implanted with SNM Axonics

Axonics secures US$40M financing to commercialise neuromodulation device

Axonics has secured US$40 million to support commercialisation of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the...